[go: up one dir, main page]

MA42678B1 - Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 - Google Patents

Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5

Info

Publication number
MA42678B1
MA42678B1 MA42678A MA42678A MA42678B1 MA 42678 B1 MA42678 B1 MA 42678B1 MA 42678 A MA42678 A MA 42678A MA 42678 A MA42678 A MA 42678A MA 42678 B1 MA42678 B1 MA 42678B1
Authority
MA
Morocco
Prior art keywords
bicyclic aromatic
nucleoside analogs
substituted nucleoside
prmt5 inhibitors
new substituted
Prior art date
Application number
MA42678A
Other languages
English (en)
Other versions
MA42678A (fr
Inventor
Lieven Meerpoel
Gaston Diels
Marcel Viellevoye
Tongfei Wu
Dirk Brehmer
Lijs Beke
An Boeckx
Ronaldus Gilissen
Edward Lawson
Vineet Pande
Marcus Parade
Wim Schepens
Johannes Thuring
Weimei Sun
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA42678A publication Critical patent/MA42678A/fr
Publication of MA42678B1 publication Critical patent/MA42678B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des analogues nucléosidiques substitués par un cycle aromatique bicyclique 6-6 de formule (i) dans laquelle les variables sont telles que définies dans les revendications. Les composés selon la présente invention sont utiles comme inhibiteurs de prmt5. L'invention concerne en outre des compositions pharmaceutiques comprenant lesdits composés comme principe actif ainsi que l'utilisation desdits composés comme médicament.
MA42678A 2015-08-26 2016-08-25 Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 MA42678B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562209941P 2015-08-26 2015-08-26
EP15184011 2015-09-07
US201662306233P 2016-03-10 2016-03-10
PCT/EP2016/070097 WO2017032840A1 (fr) 2015-08-26 2016-08-25 Nouveaux analogues nucléosidiques substitués par un cycle aromatique bicyclique 6-6 utiles comme inhibiteurs de prmt5

Publications (2)

Publication Number Publication Date
MA42678A MA42678A (fr) 2021-05-19
MA42678B1 true MA42678B1 (fr) 2021-11-30

Family

ID=54065259

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42678A MA42678B1 (fr) 2015-08-26 2016-08-25 Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5

Country Status (36)

Country Link
US (4) US10653711B2 (fr)
EP (3) EP4219496A1 (fr)
JP (3) JP6917978B2 (fr)
KR (1) KR102716092B1 (fr)
CN (1) CN107922413B (fr)
AR (1) AR105820A1 (fr)
AU (4) AU2016311295B2 (fr)
BR (2) BR122023020317A2 (fr)
CA (1) CA2992688A1 (fr)
CL (1) CL2018000510A1 (fr)
CO (1) CO2018002063A2 (fr)
CY (1) CY1125359T1 (fr)
DK (1) DK3341368T3 (fr)
EA (1) EA201890573A1 (fr)
ES (1) ES2901972T3 (fr)
HK (2) HK1253898A1 (fr)
HR (1) HRP20211997T1 (fr)
HU (1) HUE057312T2 (fr)
IL (3) IL311843A (fr)
LT (1) LT3341368T (fr)
MA (1) MA42678B1 (fr)
MD (1) MD3341368T2 (fr)
MX (2) MX2018002326A (fr)
MY (1) MY198472A (fr)
NZ (2) NZ740528A (fr)
PE (2) PE20180929A1 (fr)
PH (2) PH12018500425B1 (fr)
PL (1) PL3341368T3 (fr)
PT (1) PT3341368T (fr)
RS (1) RS62698B1 (fr)
SG (1) SG10202003775VA (fr)
SI (1) SI3341368T1 (fr)
SM (1) SMT202100725T1 (fr)
TN (1) TN2018000043A1 (fr)
TW (2) TWI791251B (fr)
WO (1) WO2017032840A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI791251B (zh) * 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
US10898504B2 (en) * 2016-03-10 2021-01-26 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
CA2969295A1 (fr) 2016-06-06 2017-12-06 Pfizer Inc. Derives de carbonucleosides substitues et leur utilisation comme inhibiteur de prmt5
HUE053907T2 (hu) 2016-09-14 2021-07-28 Janssen Pharmaceutica Nv A menin-MLL kölcsönhatás spiro-biciklusos inhibitorai
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
KR102493364B1 (ko) 2016-09-14 2023-01-27 얀센 파마슈티카 엔.브이. Menin-mll 상호작용의 융합 바이사이클릭 억제제
UA124074C2 (uk) * 2016-10-03 2021-07-14 Янссен Фармацевтика Нв Аналоги карбануклеозиду, заміщені моноциклічною та біциклічною кільцевою системою, для застосування як інгібіторів prmt5
WO2018065365A1 (fr) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
EP3555103B1 (fr) 2016-12-15 2021-09-22 Janssen Pharmaceutica NV Dérivés d'azépane en tant qu'inhibiteurs de l'interaction ménine-mll
GB201700526D0 (en) * 2017-01-12 2017-03-01 Univ Of Hull Therapeutic use
AU2018225312B2 (en) 2017-02-27 2024-02-08 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
CN111527099B (zh) 2017-08-09 2024-03-22 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
EP3700906A1 (fr) 2017-10-26 2020-09-02 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
CA3084253A1 (fr) * 2017-12-05 2019-06-13 Angex Pharmaceutical, Inc. Composes heterocycliques en tant qu'inhibiteurs de prmt5
BR112020010815A2 (pt) * 2017-12-08 2020-11-10 Janssen Pharmaceutica Nv análogos espirobicíclicos
WO2019116302A1 (fr) 2017-12-13 2019-06-20 Lupin Limited Composés hétérocycliques bicycliques substitués utilisés en tant qu'inhibiteurs de prmt5
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
PT3765461T (pt) * 2018-03-14 2023-11-14 Prelude Therapeutics Inc Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833669A4 (fr) * 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020033284A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3897667A4 (fr) * 2018-12-21 2023-04-19 Memorial Sloan Kettering Cancer Center Analogues de salicyl-adénosinemonosulfamate et leurs utilisations
CN109400545B (zh) * 2018-12-24 2022-03-25 济南大学 一种精氨酸甲基转移酶5抑制剂及其应用
CN109369507A (zh) * 2018-12-26 2019-02-22 重庆市碚圣医药科技股份有限公司 一种n-(2,2-二乙氧基乙基)邻苯二甲酰亚胺的提纯方法
AU2020223058A1 (en) * 2019-02-13 2021-09-09 Prelude Therapeutics, Incorporated Selective inhibitor of protein arginine methyltransferase 5 (PRMT5)
WO2020190073A1 (fr) * 2019-03-20 2020-09-24 한국화학연구원 Composition pharmaceutique comprenant un nouveau composé hétérocyclique azolopyrimidine en tant que principe actif
EP3947387B1 (fr) * 2019-03-25 2024-10-23 California Institute Of Technology Inhibiteurs de prmt5 et leurs utilisations
CN114072407A (zh) 2019-04-02 2022-02-18 阿里戈斯治疗公司 靶向prmt5的化合物
WO2020206289A1 (fr) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5
EP3946352A4 (fr) * 2019-04-05 2022-12-28 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5
JP2022534998A (ja) * 2019-05-30 2022-08-04 エンジェクス ファーマシューティカル インコーポレイテッド Ｐｒｍｔ５阻害剤としての複素環式化合物
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
AU2020293021A1 (en) * 2019-06-10 2021-12-23 Lupin Limited PRMT5 inhibitors
CN113966328B (zh) * 2019-06-12 2025-01-03 詹森药业有限公司 新型螺双环中间体
CA3154566A1 (fr) * 2019-09-18 2021-03-25 Prelude Therapeutics Incorporated Inhibiteurs selectifs de la proteine arginine methyltransferase 5 (prmt5)
BR112022007808A2 (pt) 2019-10-22 2022-07-05 Lupin Ltd Combinação farmacêutica de inibidores de prmt5
GB201915447D0 (en) * 2019-10-24 2019-12-11 Johnson Matthey Plc Polymorphs of avapritinib and methods of preparing the polymorphs
MX2022006735A (es) * 2019-12-03 2022-07-21 Lupin Ltd Análogos de nucleósidos sustituidos como inhibidores de la prmt5.
JP7429799B2 (ja) 2020-02-18 2024-02-08 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
CN111233869B (zh) * 2020-03-12 2022-09-16 杭州新博思生物医药有限公司 用于制备瑞德西韦关键中间体的新化合物及其制备方法
WO2021202480A1 (fr) * 2020-04-01 2021-10-07 Aligos Therapeutics, Inc. Composés ciblant prmt5
US20240101589A1 (en) * 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
CN112645875A (zh) * 2020-12-09 2021-04-13 深圳海王医药科技研究院有限公司 一种盐酸丙卡特罗杂质的制备方法
EP4323362A1 (fr) 2021-04-16 2024-02-21 Gilead Sciences, Inc. Procédés de préparation de carbanucléosides à l'aide d'amides
CN113234079B (zh) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 用作prmt5抑制剂的核苷类似物
CN117157297A (zh) * 2021-07-20 2023-12-01 上海齐鲁制药研究中心有限公司 Prmt5抑制剂
CN115703796A (zh) * 2021-08-09 2023-02-17 苏州恩泰新材料科技有限公司 一种瑞德西韦重要中间体制备方法
CA3228162A1 (fr) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Composes phospholipidiques et leurs procedes de production et d'utilisation
GB202117230D0 (en) 2021-11-29 2022-01-12 Argonaut Therapeutics Ltd Peptide vaccine
GB202203588D0 (en) 2022-03-15 2022-04-27 Argonaut Therapeutics Ltd Cancer diagnostic
CN116655638B (zh) * 2022-05-12 2024-01-26 上海齐鲁制药研究中心有限公司 氘代prmt5抑制剂
CN116003339B (zh) * 2022-12-01 2024-06-28 南京师范大学 一种巨噬细胞迁移抑制因子mif双光子荧光探针及其制备方法和应用
WO2024170488A1 (fr) 2023-02-13 2024-08-22 Astrazeneca Ab Inhibiteur de prmt5 destiné à être utilisé en thérapie anticancéreuse
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
WO2003039523A2 (fr) 2001-11-05 2003-05-15 Exiqon A/S Oligonucleotides modifies a l'aide de nouveaux analogues d'arn-l-alpha
US7034147B2 (en) 2001-11-29 2006-04-25 Irm Llc Nucleoside analog libraries
CN1636009A (zh) 2002-02-19 2005-07-06 Cv医药有限公司 A1 腺苷受体的部分和全促效药
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
US7144674B2 (en) * 2002-03-20 2006-12-05 Sumitomo Chemical Company, Limited Positive resist composition
AU2002951247A0 (en) * 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
EP1645561A1 (fr) 2003-07-15 2006-04-12 Mitsui Chemicals, Inc. Procede de synthese d'un bisdinucleoside cyclique
EP1694642A4 (fr) 2003-12-19 2010-10-06 Koronis Pharmaceuticals Inc Heterocycles mutagenes
EP1844062A2 (fr) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibiteurs d'adn-methyltransferase
WO2008001101A2 (fr) 2006-06-29 2008-01-03 Astex Therapeutics Limited Combinaisons pharmaceutiques
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
CA2737661C (fr) 2008-09-23 2019-08-20 Alnylam Pharmaceuticals, Inc. Modifications chimiques de monomeres et d'oligonucleotides par cycloaddition
JP2013514781A (ja) 2009-12-18 2013-05-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ β細胞複製促進化合物およびそれらの使用法
EP2646455A4 (fr) 2010-12-03 2014-04-02 Epizyme Inc Modulateurs d'histone méthyltransférase et leurs procédés d'utilisation
RU2013130253A (ru) * 2010-12-03 2015-01-10 Эпизайм, Инк. 7-деазапуриновые регуляторы метилтрансферазы гистонов и способы их применения
EP2651885A1 (fr) 2010-12-16 2013-10-23 Abbvie Inc. Composés antiviraux
WO2012138530A1 (fr) 2011-04-04 2012-10-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dérivés de 2'-o-aminooxyméthyl nucléoside pour l'utilisation dans la synthèse et la modification de nucléosides, nucléotides et oligonucléotides
JP2014530910A (ja) 2011-10-24 2014-11-20 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ 新規化合物
WO2013151975A1 (fr) 2012-04-02 2013-10-10 Northeastern University Compositions et procédés d'inhibition de méthyltransférases
WO2014035140A2 (fr) * 2012-08-30 2014-03-06 Kainos Medicine, Inc. Composés et compositions pour la modulation de l'activité histone méthyltransférase
US20140100184A1 (en) 2012-08-31 2014-04-10 Baylor College Of Medicine Selective inhibitors of histone methyltransferase dot1l
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US8906900B2 (en) 2012-12-21 2014-12-09 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2014100716A1 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
BR112015014590B1 (pt) 2012-12-21 2022-12-20 Epizyme, Inc Composto, composição farmacêutica e estojo ou farmacêutico empacotado
US9856218B2 (en) 2013-03-15 2018-01-02 Ohio State Innovation Foundation Inhibitors of PRMT5 and methods of their use
CA2935944A1 (fr) 2014-01-09 2015-07-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Benzoxazine substituee et composes associes
WO2015200680A2 (fr) 2014-06-25 2015-12-30 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
UY36198A (es) 2014-07-01 2016-01-29 Millennium Pharm Inc Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo
CR20170384A (es) 2015-02-24 2017-11-16 Pfizer Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
CA3016096C (fr) 2016-03-10 2023-10-17 Janssen Pharmaceutica Nv Analogues de nucleosides substitues destines a etre utilises en tant qu'inhibiteurs de prmt5
WO2018065365A1 (fr) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
UA124074C2 (uk) * 2016-10-03 2021-07-14 Янссен Фармацевтика Нв Аналоги карбануклеозиду, заміщені моноциклічною та біциклічною кільцевою системою, для застосування як інгібіторів prmt5
AU2018225312B2 (en) 2017-02-27 2024-02-08 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
BR112020010815A2 (pt) 2017-12-08 2020-11-10 Janssen Pharmaceutica Nv análogos espirobicíclicos

Also Published As

Publication number Publication date
IL311843A (en) 2024-05-01
KR20180041222A (ko) 2018-04-23
BR112018003595A2 (pt) 2018-09-25
PE20221629A1 (es) 2022-10-19
US20230330127A1 (en) 2023-10-19
EP3974428A1 (fr) 2022-03-30
SI3341368T1 (sl) 2022-01-31
BR122023020317A2 (pt) 2023-12-12
CL2018000510A1 (es) 2018-07-06
AU2022215260B2 (en) 2024-04-18
IL257664A (en) 2018-04-30
US11318157B2 (en) 2022-05-03
SG10202003775VA (en) 2020-06-29
US20230071711A1 (en) 2023-03-09
NZ779003A (en) 2024-12-20
MX2018002326A (es) 2018-04-11
PE20180929A1 (es) 2018-06-08
CN107922413B (zh) 2021-10-01
MY198472A (en) 2023-08-31
CO2018002063A2 (es) 2018-07-19
HK1257099A1 (zh) 2019-10-11
JP2018528946A (ja) 2018-10-04
TW202146414A (zh) 2021-12-16
KR102716092B1 (ko) 2024-10-10
AU2016311295A1 (en) 2018-02-08
MX2022005182A (es) 2022-05-16
AR105820A1 (es) 2017-11-15
EA201890573A1 (ru) 2018-07-31
US11883367B2 (en) 2024-01-30
LT3341368T (lt) 2021-12-10
WO2017032840A1 (fr) 2017-03-02
PH12021552054A1 (en) 2022-05-02
DK3341368T3 (da) 2021-12-20
CA2992688A1 (fr) 2017-03-02
MA42678A (fr) 2021-05-19
ES2901972T3 (es) 2022-03-24
HRP20211997T1 (hr) 2022-04-01
HUE057312T2 (hu) 2022-05-28
AU2022215260A1 (en) 2022-09-01
JP6917978B2 (ja) 2021-08-11
JP2024012405A (ja) 2024-01-30
AU2021200345A1 (en) 2021-03-18
AU2016311295B2 (en) 2020-10-22
TWI791251B (zh) 2023-02-01
PH12018500425B1 (en) 2022-09-02
CN114057815A (zh) 2022-02-18
AU2021200345B2 (en) 2022-08-04
NZ740528A (en) 2024-11-29
TW202321249A (zh) 2023-06-01
JP2021169520A (ja) 2021-10-28
TWI730980B (zh) 2021-06-21
CY1125359T1 (el) 2024-02-16
US20180243328A1 (en) 2018-08-30
AU2024202052A1 (en) 2024-04-18
EP3341368B1 (fr) 2021-10-06
PL3341368T3 (pl) 2022-02-14
HK1253898A1 (zh) 2019-07-05
RS62698B1 (sr) 2022-01-31
PH12018500425A1 (en) 2018-09-10
MD3341368T2 (ro) 2022-02-28
IL282537A (en) 2021-06-30
PT3341368T (pt) 2021-12-09
TW201718575A (zh) 2017-06-01
TN2018000043A1 (en) 2019-07-08
BR112018003595B1 (pt) 2024-03-12
CN107922413A (zh) 2018-04-17
SMT202100725T1 (it) 2022-01-10
US10653711B2 (en) 2020-05-19
EP4219496A1 (fr) 2023-08-02
IL257664B (en) 2021-05-31
US20200360416A1 (en) 2020-11-19
EP3341368A1 (fr) 2018-07-04

Similar Documents

Publication Publication Date Title
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA46101B1 (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA42339A1 (fr) Modulateurs du récepteur farnésoïde x
TN2011000659A1 (fr) Formulation pharmaceutique
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MA50804B1 (fr) Nouveaux antagonistes des récepteurs de bradykinine b2
MA39335B1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
MA38330A1 (fr) Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre)
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
EA201490222A1 (ru) Комбинированные составы на основе дарунавира
MA39983B1 (fr) Dérivés de carboxamide
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA39750B1 (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
MA37879B1 (fr) Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant